Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Once-daily aminoglycosides: practical guidelines

J M Prins1, P Speelman

  • 1Academic Medical Centre, Department of Internal Medicine, Amsterdam, Netherlands. j.m.prins@amc.uva.nl

The Netherlands Journal of Medicine
|May 9, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Vertebral osteomyelitis in patients with infective endocarditis: prevalence, risk factors and mortality.

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology·2025
Same author

Correction to: Comparative effectiveness of β-lactams for empirical treatment of methicillin-susceptible Staphylococcus aureus bacteraemia: a prospective cohort study.

The Journal of antimicrobial chemotherapy·2023
Same author

Safe shortening of antibiotic treatment duration for complicated <i>Staphylococcus aureus</i> bacteraemia (SAFE trial): protocol for a randomised, controlled, open-label, non-inferiority trial comparing 4 and 6 weeks of antibiotic treatment.

BMJ open·2023
Same author

Comparative effectiveness of β-lactams for empirical treatment of methicillin-susceptible Staphylococcus aureus bacteraemia: a prospective cohort study.

The Journal of antimicrobial chemotherapy·2023
Same author

Exposure and virologic outcomes of dolutegravir combined with ritonavir boosted darunavir in treatment-naïve individuals enrolled in the Netherlands Cohort Study on Acute HIV infection (NOVA).

International journal of antimicrobial agents·2022
Same author

The effect of the acute phase of infection on absorption of and exposure to orally administered antibiotics in non-critically ill, hospitalized patients.

The Journal of antimicrobial chemotherapy·2022
Same journal

A diagnostic tool for self-poisoned patients: Analysis of gastric content and lavage fluids.

The Netherlands journal of medicine·2020
Same journal

Answer to Photoquiz A bone disorder with skin lesions.

The Netherlands journal of medicine·2020
Same journal

A bone disorder with skin lesions.

The Netherlands journal of medicine·2020
Same journal

Answer to Photoquiz A fascinating liver abscess.

The Netherlands journal of medicine·2020
Same journal

A fascinating liver abscess.

The Netherlands journal of medicine·2020
Same journal

Answer to Photoquiz A polyposis syndrome.

The Netherlands journal of medicine·2020
See all related articles

Once-daily aminoglycoside dosing is preferred for serious infections and is safe in children and neutropenic patients. Further study is needed for cystic fibrosis patients and optimal monitoring in renal failure.

Area of Science:

  • Pharmacology
  • Infectious Diseases
  • Clinical Pharmacy

Background:

  • Conventional aminoglycoside dosing regimens may not be optimal for treating serious infections.
  • Evidence suggests once-daily aminoglycoside administration offers advantages over traditional multi-daily dosing.

Purpose of the Study:

  • To evaluate the efficacy and safety of once-daily aminoglycoside dosing.
  • To assess the applicability of this regimen in specific patient populations, including children, neutropenic patients, and those with endocarditis.
  • To explore dose-adjustment strategies for patients with renal failure and discuss the role of serum level monitoring.

Main Methods:

  • Review of experimental and clinical studies on aminoglycoside dosing.
  • Analysis of pharmacokinetic data in various patient groups.

Related Experiment Videos

  • Evaluation of safety and efficacy data for once-daily versus conventional dosing.

    • Main Results:

    • Once-daily aminoglycoside dosing is generally preferable to conventional regimens for serious infections.
    • The once-daily regimen is safe in children, neutropenic patients, and endocarditis treatment.
    • Dose reduction while maintaining once-daily intervals is a safe strategy for renal failure patients.
    • Tobramycin use in cystic fibrosis requires further investigation due to altered pharmacokinetics.
    • The role of serum level monitoring in preventing aminoglycoside accumulation needs further definition.

    Conclusions:

    • Once-daily aminoglycoside dosing is an effective and safe strategy for many serious infections.
    • Specific patient populations require tailored approaches and further research, particularly those with cystic fibrosis and renal impairment.
    • Optimizing aminoglycoside therapy necessitates a balanced approach to dosing, monitoring, and patient-specific factors to avoid toxicity and ensure efficacy.